WATERTOWN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Evercore ISI 3rd Annual HealthCONx on Thursday, December 3, 2020 at 8:25 a.m. ET.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.
About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.
CONTACT: Investor & Media Contact: Kendra Adams SVP, Communications & Investor Relations Kendra.Adams@c4therapeutics.com
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…
Juno Health Rated Highest Overall in Key "Future-Ready" Measures for Small and Rural Hospitals; RHT…
NAPLES, FL / ACCESS Newswire / February 3, 2026 / Stemtech Corporation, the global leader…
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into…
ESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American…